Try
Kiniksa Pharmaceuticals International, plc
KNSAUnited States
41 filed reports · 347 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
41 reports · Jun 2018 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 16 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 25 | 3,056 | Jun 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 8 | 2,583 | Dec 2018 to Dec 2025 |
| Current · 8-KSEC EDGAR | 8 | 16 | Jun 2021 to Jun 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 28, 2026 | 300 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 28, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 28, 2026 | 173 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 675 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 28, 2025 | 197 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 29, 2025 | 139 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 29, 2025 | 136 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 25, 2025 | 321 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 29, 2024 | 138 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Jul 25, 2024 | 112 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | Apr 25, 2024 | 120 | Open |
| FY2024 Q1 | 8-K | Mar 31, 2024 | Apr 23, 2024 | 2 | Open |
Financial data
347 concepts · 5,655 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial321 concepts · 5,424 facts · Dec 2016 to Jun 2026
- Balance at end of period104 · Jun 2021 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents48 · Dec 2016 to Jun 2026
- Allocated share based compensation expense46 · Jun 2017 to Jun 2026
- Depreciation46 · Jun 2017 to Jun 2026
- Income tax expense benefit46 · Jun 2017 to Jun 2026
- Net income loss46 · Jun 2017 to Jun 2026
- Operating income loss46 · Jun 2017 to Jun 2026
- Research and development expense46 · Jun 2017 to Jun 2026
- Stockholders equity (US GAAP)46 · Dec 2016 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect45 · Sep 2017 to Jun 2026
- Increase decrease in accounts payable45 · Sep 2017 to Jun 2026
- Increase decrease in accrued liabilities45 · Sep 2017 to Jun 2026
- Net cash provided by used in financing activities45 · Sep 2017 to Jun 2026
- Net cash provided by used in investing activities45 · Sep 2017 to Jun 2026
- Net cash provided by used in operating activities45 · Sep 2017 to Jun 2026
- Profit loss45 · Sep 2017 to Jun 2026
- Share based compensation45 · Sep 2017 to Jun 2026
- Accounts payable current43 · Dec 2017 to Jun 2026
- Accrued liabilities current43 · Dec 2017 to Jun 2026
- Accrued professional fees current43 · Dec 2017 to Jun 2026
- Accrued research and development expenses43 · Dec 2017 to Jun 2026
- Accumulated depreciation depletion and amortization property plant and equipment43 · Dec 2017 to Jun 2026
- Additional paid in capital43 · Dec 2017 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value43 · Dec 2017 to Jun 2026
Segment14 concepts · 120 facts · Dec 2023 to Jun 2026
- Revenue47 · Dec 2023 to Jun 2026
- Property, Plant & Equipment, Net21 · Dec 2024 to Jun 2026
- Investment income interest8 · Mar 2024 to Jun 2026
- Collaboration expenses4 · Mar 2024 to Jun 2025
- Cost of goods and services sold (US GAAP)4 · Mar 2024 to Jun 2025
- Deferred income tax expense benefit4 · Mar 2024 to Jun 2025
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest4 · Mar 2024 to Jun 2025
- Income tax expense benefit4 · Mar 2024 to Jun 2025
- Net income loss4 · Mar 2024 to Jun 2025
- Non-cash lease expense4 · Mar 2024 to Jun 2025
- Other nonoperating income4 · Mar 2024 to Jun 2025
- Selling general and administrative expense4 · Mar 2024 to Jun 2025
- Share based compensation4 · Mar 2024 to Jun 2025
- Total operating expenses4 · Mar 2024 to Jun 2025
Product4 concepts · 64 facts · Jun 2021 to Jun 2026
- Revenue41 · Jun 2021 to Jun 2026
- Cost of goods and services sold (US GAAP)18 · Jun 2021 to Dec 2023
- Accounts Receivable, Net3 · Dec 2021 to Jun 2022
- Collaboration expenses2 · Mar 2022 to Mar 2023
Geography7 concepts · 31 facts · Dec 2018 to Dec 2025
- Property, Plant & Equipment, Net12 · Dec 2021 to Dec 2024
- Effective income tax rate reconciliation at federal statutory income tax rate6 · Mar 2024 to Dec 2025
- Income tax reconciliation income tax expense benefit at federal statutory income tax rate6 · Dec 2024 to Dec 2025
- Income loss from continuing operations before income taxes foreign2 · Dec 2018 to Dec 2019
- U.S. federal2 · Dec 2018 to Dec 2019
- U.S. state2 · Dec 2018 to Dec 2019
- Current foreign tax expense benefit1 · Dec 2019
Guidance1 concepts · 16 facts · Aug 2021 to Jul 2026
- Revenue Guidance16 · Aug 2021 to Jul 2026
Segments
215 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments2 members · 120 facts
- Pharmaceutical99 · Dec 2023 to Jun 2026
- Pharmaceutical segment21 · Dec 2024 to Jun 2026
Product or service3 members · 64 facts
- Product39 · Jun 2021 to Jun 2026
- Collaboration22 · Dec 2021 to Dec 2024
- Product3 · Dec 2021 to Jun 2022
Statement geographical5 members · 31 facts
- BM12 · Mar 2024 to Dec 2025
- Gb12 · Dec 2021 to Dec 2024
- US4 · Dec 2018 to Dec 2019
- United States United Kingdom Germany And France2 · Dec 2018 to Dec 2019
- United Kingdom Germany And France1 · Dec 2019
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 28, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.